ABSITE 2023 Exam Questions and Answers
(Latest Update 2024)
MC umodel ufor uthe udissemination uand uimplementation uof uevidence-based ubest upractices
u - uANS-RE-AIM
Adjustment ufor utrough ubeing utoo uhigh u- uANS-DECREASE ufrequency uof uadministered
u antibiotic u(increase utime ubetween udosing)
Immunohistochemical ustain uthat udifferentiates uEpithelioid uhemangioendothelioma ufrom
u other unonvascular utumors? u- uANS-Factor uVII
Best upredictor uof ulong-term usuccess uin upatients uwith uTBI u- uANS-Post-resuscitation uGCS
u (not uinitial)
Cardiac uallograft urejection u- uANS-Usually uasymptomatic, usteroid utreatment uin ufirst u3
u months uof urejection
T-cell umediated
Pathophysiology ubehind urefeeding usyndrome u- uANS-Sudden uinflux uof uphosphate uinto
u cells utriggered uby uthe uresumption uof uadenosine utriphosphate uproduction, uwhich uresults
u in uhypophosphatemia.
,Pneumobilia uvs. uportal uvenous ugas u- uANS-Pneumobilia: uCentral
Portal uvenous ugas: uPeripheral
Immunosuppressive uagent uwith uthe uhighest urate uof upost-transplant unew uonset udiabetes
u - uANS-Tacrolimus
MC uorganism uin uSBP u- uANS-E.coli u(usually umonomicrobial)
If upolymicrobial, uconcern ufor uperforated uviscus
MCC uof ubenign ubiliary ustricture u- uANS-Previous ucholecystectomy
Primary ulymphoid uorgans u- uANS-"The uBest uLymphoid" uThymus, uBone, uLiver
Treatment ufor uSCC uof uproximal uesophagus u- uANS-Definitive uchemoradiation
Adrenal-lytic uused ufor urecurrent, uresidual, uor umetastatic udisease u- uANS-Mitotane
Hypomagnesemia ucan uled uto uwhich uelectrolyte udeficiencies u- uANS-Hypokalemia uand
u hypocalcemia
,Treatment uof uventral uhernia uin udialysis upatients uabout uto uget uPD ucatheter uplaced u-
u ANS-Repair uhernia uwith uextraperitoneal umesh uand uplace uPD ucatheter uat usame utime
MC umalignant utumor uof uthe usmall ubowel u- uANS-Mets ufrom uanother uprimary
u (MELANOMA)
MC uprimary umalignant utumor uof uthe usmall ubowel u- uANS-Adenocarcinoma u(rare)
Medical umanagement ufor upatients uwith udesmoid utumors uwith uhigh urisk uor uhave uhigh
u morbidity uif umanaged usurgically, usuch uas uthose uinvolving uthe umesentery, umajor
u vessels, uor uother ucritical ustructures u- uANS-NSAIDs uand uTamoxifen
Initiating uevent uin uthe uformation uof uascites u- uANS-Sinusoidal uportal uhypertension
Antibiotic ure-dosing ufor ucolon uprocedures u- uANS-Re-dose uif u> u2 uhours uor uif usignificant
u blood uloss
Surgical umanagement uof uduodenal utumors uless uthan u1 ucm uin udiameter u- uANS-
Endoscopic upolypectomy
VTE uprophylaxis uin upatients uundergoing umajor uabdominal/pelvic uoperations ufor ucancer u-
u ANS-Subcutaneous uLMWH ufor u28 udays
, Work-up ufor uchildren uwith ucervical ulymphadenopathy u- uANS-< u2cm: u2 uweek ufollow uup uif
u non-tender, umobile
>/= u2cm: uCBC, uESR, uCRP, uCXR
u - uIf uconcerning ufeatures u-> ubiopsy
u - uIf unot, u10-14 udays uabx uwith ufollow uup
Primary ucancer umost ulikely uto umets uto uthe uadrenal uglands u- uANS-Lung
Reversal uof uClopidogrel u- uANS-Transfused upooled uplatelets, uDesmopressin
Which uimmunotherapy uagent utargets uPD-L1 uand uwhat ucaner uis uit uused ufor? u- uANS-
Pembrolizumab, uNSCLC
Which uimmunotherapy uagent utargets uRET uand uwhat ucaner uis uit uused ufor? u- uANS-
Selpercatinib, umedullary uthyroid ucancer uin uMEN u2A/2B
Which uimmunotherapy uagent utargets uCTLA-4 uand uwhat ucaner uis uit uused ufor? u- uANS-
Ipilimumab, uMelanoma
Symptoms uof ugastrogastric ufistula uafter uRYGB u- uANS-Recurrent ureflux uand uweight ugain
Diagnose uwith uUGIS uor uCT uw/ uPO ucontrast
(Latest Update 2024)
MC umodel ufor uthe udissemination uand uimplementation uof uevidence-based ubest upractices
u - uANS-RE-AIM
Adjustment ufor utrough ubeing utoo uhigh u- uANS-DECREASE ufrequency uof uadministered
u antibiotic u(increase utime ubetween udosing)
Immunohistochemical ustain uthat udifferentiates uEpithelioid uhemangioendothelioma ufrom
u other unonvascular utumors? u- uANS-Factor uVII
Best upredictor uof ulong-term usuccess uin upatients uwith uTBI u- uANS-Post-resuscitation uGCS
u (not uinitial)
Cardiac uallograft urejection u- uANS-Usually uasymptomatic, usteroid utreatment uin ufirst u3
u months uof urejection
T-cell umediated
Pathophysiology ubehind urefeeding usyndrome u- uANS-Sudden uinflux uof uphosphate uinto
u cells utriggered uby uthe uresumption uof uadenosine utriphosphate uproduction, uwhich uresults
u in uhypophosphatemia.
,Pneumobilia uvs. uportal uvenous ugas u- uANS-Pneumobilia: uCentral
Portal uvenous ugas: uPeripheral
Immunosuppressive uagent uwith uthe uhighest urate uof upost-transplant unew uonset udiabetes
u - uANS-Tacrolimus
MC uorganism uin uSBP u- uANS-E.coli u(usually umonomicrobial)
If upolymicrobial, uconcern ufor uperforated uviscus
MCC uof ubenign ubiliary ustricture u- uANS-Previous ucholecystectomy
Primary ulymphoid uorgans u- uANS-"The uBest uLymphoid" uThymus, uBone, uLiver
Treatment ufor uSCC uof uproximal uesophagus u- uANS-Definitive uchemoradiation
Adrenal-lytic uused ufor urecurrent, uresidual, uor umetastatic udisease u- uANS-Mitotane
Hypomagnesemia ucan uled uto uwhich uelectrolyte udeficiencies u- uANS-Hypokalemia uand
u hypocalcemia
,Treatment uof uventral uhernia uin udialysis upatients uabout uto uget uPD ucatheter uplaced u-
u ANS-Repair uhernia uwith uextraperitoneal umesh uand uplace uPD ucatheter uat usame utime
MC umalignant utumor uof uthe usmall ubowel u- uANS-Mets ufrom uanother uprimary
u (MELANOMA)
MC uprimary umalignant utumor uof uthe usmall ubowel u- uANS-Adenocarcinoma u(rare)
Medical umanagement ufor upatients uwith udesmoid utumors uwith uhigh urisk uor uhave uhigh
u morbidity uif umanaged usurgically, usuch uas uthose uinvolving uthe umesentery, umajor
u vessels, uor uother ucritical ustructures u- uANS-NSAIDs uand uTamoxifen
Initiating uevent uin uthe uformation uof uascites u- uANS-Sinusoidal uportal uhypertension
Antibiotic ure-dosing ufor ucolon uprocedures u- uANS-Re-dose uif u> u2 uhours uor uif usignificant
u blood uloss
Surgical umanagement uof uduodenal utumors uless uthan u1 ucm uin udiameter u- uANS-
Endoscopic upolypectomy
VTE uprophylaxis uin upatients uundergoing umajor uabdominal/pelvic uoperations ufor ucancer u-
u ANS-Subcutaneous uLMWH ufor u28 udays
, Work-up ufor uchildren uwith ucervical ulymphadenopathy u- uANS-< u2cm: u2 uweek ufollow uup uif
u non-tender, umobile
>/= u2cm: uCBC, uESR, uCRP, uCXR
u - uIf uconcerning ufeatures u-> ubiopsy
u - uIf unot, u10-14 udays uabx uwith ufollow uup
Primary ucancer umost ulikely uto umets uto uthe uadrenal uglands u- uANS-Lung
Reversal uof uClopidogrel u- uANS-Transfused upooled uplatelets, uDesmopressin
Which uimmunotherapy uagent utargets uPD-L1 uand uwhat ucaner uis uit uused ufor? u- uANS-
Pembrolizumab, uNSCLC
Which uimmunotherapy uagent utargets uRET uand uwhat ucaner uis uit uused ufor? u- uANS-
Selpercatinib, umedullary uthyroid ucancer uin uMEN u2A/2B
Which uimmunotherapy uagent utargets uCTLA-4 uand uwhat ucaner uis uit uused ufor? u- uANS-
Ipilimumab, uMelanoma
Symptoms uof ugastrogastric ufistula uafter uRYGB u- uANS-Recurrent ureflux uand uweight ugain
Diagnose uwith uUGIS uor uCT uw/ uPO ucontrast
